72
Participants
Start Date
October 22, 2021
Primary Completion Date
June 10, 2025
Study Completion Date
June 10, 2025
vudalimab + carboplatin + cabazitaxel
Vudalimab IV, carboplatin IV, cabazitaxel IV
vudalimab + olaparib
Vudalimab IV, olaparib oral
vudalimab monotherapy
Vudalimab IV
vudalimab + docetaxel
Vudalimab IV, docetaxel IV
vudalimab + cabazitaxel or docetaxel
Vudalimab IV, cabazitaxel or docetaxel IV
Columbia University, New York
Montefiore Medical Center, The Bronx
UPMC Hillman Cancer Center, Pittsburgh
University of Pennsylvania, Philadelphia
Virginia Cancer Specialists, Fairfax
Virginia Oncology Associates, Norfolk
Carolina Urologic Research Center, Myrtle Beach
Mayo Clinic, Jacksonville
SCRI Oncology Partners, Nashville
University of Iowa Hospitals & Clinics, Iowa City
Mayo Clinic, Rochester
The University of Chicago Medical Center, Chicago
University of Kansas Clinical Research Center, Fairway
GU Research Network/Urology Cancer Center, Omaha
Texas Oncology-Central South, Weslaco
Rocky Mountain Cancer Centers, Lone Tree
Mayo Clinic Hospital, Phoenix
Palo Verde Hematology Oncology, Glendale
XCancer New Mexico Oncology Hematology Consultants, Ltd., Albuquerque
Comprehensive Cancer Centers of Nevada, Las Vegas
VA Greater Los Angeles, Los Angeles
City of Hope, Duarte
University of California, San Diego, San Diego
Northwest Cancer Specialists, Tigard
University of Washington/Seattle Cancer Care/Alliance, Seattle
Alaska Oncology and Hematology, Anchorage
Xencor, Inc.
INDUSTRY